SCHEMBL15730308

SCHEMBL15730308

CO[C@@H]1OC(CO)[C@@H](O)[C@H](O[C@@H]2OC(CO)[C@@H](O)[C@H](O[C@@H]3OC(CO)[C@@H](O)[C@H](O)C3O)C2O)C1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LGALS8 O00214 3/20 0.56
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ CD209 Q9NNX6 1/20 0.48
▸ LGALS3 P17931 2/20 0.48
▸ LGALS4 P56470 1/20 0.48
▸ GJA1 P17302 1/20 0.47
▸ GJB2 P29033 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ LGALS9 O00182 1/20 0.46
▸ LGALS1 P09382 1/20 0.46
▸ LGALS7; LGALS7B P47929 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ENGASE Q8NFI3 1/20 0.46
▸ FGF1 P05230 1/20 0.46
▸ FGF2 P09038 1/20 0.46
▸ VEGFA P15692 1/20 0.46
▸ HPSE Q9Y251 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5526345 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL5514966 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL20034302 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL16316509 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL4260234 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL6415085 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL6820046 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL4285005 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL4280409 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3
SCHEMBL4284998 1.00 LGALS8 (0.56) LGALS8MEN1KMT2ACD209LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140141034-A1 TYROSINE LIGATION PROCESS NOVARTIS AG (CH) 2014-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140141034-A1 TYROSINE LIGATION PROCESS ACP1, LTK, TTL LGALS8 376/4885MEN1 1156/4885KMT2A 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback